Jenburkt Pharmaceuticals Elevates Prem Bhuta to AVP Strategic Initiatives
Jenburkt Pharmaceuticals Ltd 路 Change in Management 路 04 Sept 2026, 6:10 pm
Jenburkt Pharmaceuticals Elevates Prem Bhuta to AVP Strategic Initiatives Jenburkt Pharmaceuticals has elevated Prem Ashish Bhuta to Associate Vice President of Strategic Initiatives, effective 4th Sep'26. As a newly designated Senior Management Personnel related to the Promoter and CMD, Bhuta will drive cross-functional business transformation. Since joining in Jul'21, he has demonstrated strong operational capability by building the ZIXA Strong OTC brand and executing critical technology modernizations, including deploying a real-time sales tracking system for a 700-member field force. His advancement signals leadership continuity and a strategic focus on digital integration within Jenburkt's operations.
Original exchange filing (PDF)
More announcements from Jenburkt Pharmaceuticals Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd 路 04 Nov 2026
- Outcome of the Board Meeting held today on 03rd November, 2026. 路 03 Nov 2026
- Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026. 路 03 Nov 2026
- Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Standalone Unaudited .... 路 03 Nov 2026
- The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd 路 12 Oct 2026
- Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited. 路 22 Sept 2026
- Intimation about Resignation of a Senior Management Personnel of the Company. 路 18 Sept 2026
- Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April, 2027 to 31st March, 2032, Approved with requisite .... 路 05 Sept 2026
